GeoVax

GeoVax

A biotechnology company developing human vaccines against infectious diseases and cancers. It was founded in 2001 and is located in Smyrna, Georgia.

GeoVax is a Georgia-based clinical-stage biotechnology company with a focus on researching and developing vaccines for illnesses including HIV, Ebola, HBV, HPV, and for cancer immunotherapy. The company designs its programs around a novel platform that integrates its recombinant Modified Vaccinia Ankara (MVA) vector technology with antigen design and manufacturing technologies.

COVID-19

In 2020, the company partnered with BravoVax, a Chinese pharmaceutical testing and manufacturing company. GeoVax had been conducting research for a vaccine for COVID-19 and developed three vaccine candidates. The company stated that it would narrow it down to one candidate and upon approval, commence animal studies with the vaccine.

Timeline

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
GeoVax Labs, Inc. funding round, December 2013
1,650,000
December 2013
1,500,000, 1,500,000
January 2012
6 Results
Results per page:
Page 1 of 1

People

Name
Role
LinkedIn

David Dodd

CEO

Harriet L. Robinson

Co-Founder

Further reading

Title
Author
Link
Type
Date

GeoVax Progresses in Coronavirus (COVID-19) Vaccine Development Program

GeoVax, Inc.

Web

March 18, 2020

Documentaries, videos and podcasts

Title
Date
Link

Cobb company to soon begin testing possible vaccines for COVID-19

Companies

Company
CEO
Location
Products/Services

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.